ACLX Quote, Financials, Valuation and Earnings

Daré Bioscience, Inc. has a net margin of -1127.12% compared to Arcellx, Inc.'s net margin of -154904.35%. Arcellx, Inc.'s return on equity of -49.8% beat Daré Bioscience, Inc.'s return on equity of --.

Arcellx, Inc. has a consensus price target of $113.13, signalling upside risk potential of 65.27%. On the other hand Daré Bioscience, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 500.56%. Given that Daré Bioscience, Inc. has higher upside potential than Arcellx, Inc., analysts believe Daré Bioscience, Inc. is more attractive than Arcellx, Inc..

Arcellx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Daré Bioscience, Inc. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.917%.

Arcellx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Daré Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx, Inc. pays -- of its earnings as a dividend. Daré Bioscience, Inc. pays out -- of its earnings as a dividend.

Arcellx, Inc. quarterly revenues are $4.9M, which are larger than Daré Bioscience, Inc. quarterly revenues of $2.3K. Arcellx, Inc.'s net income of -$55.8M is lower than Daré Bioscience, Inc.'s net income of -$3.6M. Notably, Arcellx, Inc.'s price-to-earnings ratio is -- while Daré Bioscience, Inc.'s PE ratio is 95.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx, Inc. is 106.00x versus 361.34x for Daré Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Geron Corp. has a net margin of -1127.12% compared to Arcellx, Inc.'s net margin of -39.02%. Arcellx, Inc.'s return on equity of -49.8% beat Geron Corp.'s return on equity of -29.65%.

Arcellx, Inc. has a consensus price target of $113.13, signalling upside risk potential of 65.27%. On the other hand Geron Corp. has an analysts' consensus of $3.50 which suggests that it could grow by 162.47%. Given that Geron Corp. has higher upside potential than Arcellx, Inc., analysts believe Geron Corp. is more attractive than Arcellx, Inc..

Arcellx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Geron Corp. has a beta of 0.567, suggesting its less volatile than the S&P 500 by 43.26%.

Arcellx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.

Arcellx, Inc. quarterly revenues are $4.9M, which are smaller than Geron Corp. quarterly revenues of $47.2M. Arcellx, Inc.'s net income of -$55.8M is lower than Geron Corp.'s net income of -$18.4M. Notably, Arcellx, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx, Inc. is 106.00x versus 4.61x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences, Inc. has a net margin of -1127.12% compared to Arcellx, Inc.'s net margin of 39.21%. Arcellx, Inc.'s return on equity of -49.8% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

Arcellx, Inc. has a consensus price target of $113.13, signalling upside risk potential of 65.27%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $130.63 which suggests that it could grow by 6.54%. Given that Arcellx, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Arcellx, Inc. is more attractive than Gilead Sciences, Inc..

Arcellx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.

Arcellx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.56% to investors and pays a quarterly dividend of $0.79 per share. Arcellx, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.

Arcellx, Inc. quarterly revenues are $4.9M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. Arcellx, Inc.'s net income of -$55.8M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Arcellx, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 18.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx, Inc. is 106.00x versus 5.30x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cartesian Therapeutics, Inc. has a net margin of -1127.12% compared to Arcellx, Inc.'s net margin of -7942.92%. Arcellx, Inc.'s return on equity of -49.8% beat Cartesian Therapeutics, Inc.'s return on equity of --.

Arcellx, Inc. has a consensus price target of $113.13, signalling upside risk potential of 65.27%. On the other hand Cartesian Therapeutics, Inc. has an analysts' consensus of $35.29 which suggests that it could grow by 430.61%. Given that Cartesian Therapeutics, Inc. has higher upside potential than Arcellx, Inc., analysts believe Cartesian Therapeutics, Inc. is more attractive than Arcellx, Inc..

Arcellx, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cartesian Therapeutics, Inc. has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.39%.

Arcellx, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cartesian Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx, Inc. pays -- of its earnings as a dividend. Cartesian Therapeutics, Inc. pays out -- of its earnings as a dividend.

Arcellx, Inc. quarterly revenues are $4.9M, which are larger than Cartesian Therapeutics, Inc. quarterly revenues of $452K. Arcellx, Inc.'s net income of -$55.8M is lower than Cartesian Therapeutics, Inc.'s net income of -$35.9M. Notably, Arcellx, Inc.'s price-to-earnings ratio is -- while Cartesian Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx, Inc. is 106.00x versus 74.19x for Cartesian Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.